DV
Dividend Vision

ATAI — AtaiBeckley Inc.

AtaiBeckley Inc. (ATAI)

Total return is -62.7% over the past 5.2 years, 162.9 points behind SPY at 100.2%. Its deepest 1-year drawdown was 48.1%.

AtaiBeckley Inc. is a clinical-stage biopharmaceutical company developing mental health treatments, including candidates in clinical trials for treatment-resistant depression, alcohol use disorder, cognitive impairment, and other psychiatric conditions. The company operates primarily in the United States, Germany, and Canada, with a pipeline spanning multiple modalities from intranasal formulations to psychedelic compounds. AtaiBeckley does not currently have an established distribution history, and as an early-stage biotech company, it may appeal primarily to investors seeking exposure to growth-oriented opportunities in the mental health treatment space rather than income-focused investors.

ATAI key facts

Asset type
Stock
Asset class
Equity
Inception date
06/18/2021
Distribution frequency
None
Last close
$7.26
Market cap
$2,692,477,696
Average volume
6098100.0
Beta
1.553
Payout ratio
0.0
Forward P/E
0.0
EPS
$-2.80